QIAGEN and BioHelix Enter Into Licensing Agreement
Helicase-dependent isothermal DNA amplification system provides new assay technology capabilities for QIAGEN's assay automation platforms
QIAGEN and privately held BioHelix have announced that they have entered into a non-exclusive worldwide license and supply agreement for BioHelix's proprietary Helicase Dependent Amplification technology (HDA). HDA is a versatile assay technology to detect and analyze biological target molecules such as DNA and RNA by amplifying target specific genetic information with the highest level of sensitivity and specificity. Financial terms were not disclosed.
Unlike conventional amplification technologies such as the polymerase chain reaction (PCR), which requires thermocycling, HDA works at a constant temperature, eliminating the need for complex and costly instrumentation. In addition HDA technology offers a simple reaction workflow and a user-friendly assay design process. Two primers are used to flank the DNA fragment to be amplified, thereby allowing simple and rapid development of new singleplex and/or multiplex assays for use in research, pharmaceutical development, applied markets or molecular diagnostics.
Furthermore, HDA has shown potential for the development of simple, portable DNA diagnostic devices to be used in the field or at the point-of-care..
Most read news
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Last viewed contents

AI performs as well as medical specialists in analyzing lung disease
Merck Advances to Eighth Place in the 2012 Access to Medicine Index
Evonik achieves major biotech breakthrough with a new animal-free and fermentation-based collagen platform - Recombinant collagen mimics attributes of human collagen

Bacteria Free Themselves with Molecular “Speargun”

Paper-based device developed for rapid diagnosis of lung diseases - CSIC researchers have coordinated the design of an instrument that combines paper microfluidics and electrochemical transduction.
SciGene Moves to Larger Manufacturing and Research Space
Complex production and sales processes weaken a company's competitiveness - Engineering, chemicals and pharmaceuticals need to catch up
Innogenetics extends its diagnostics product portfolio for Alzheimer's disease with new products

Next generation of viral vectors, called AAV 3.0, for gene therapies and genome editing
AmpliPhi and Special Phage Services complete merger
